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A B S T R A C T
Background
Tuberculous meningitis is a serious form of tuberculosis (TB) that affects the meninges that cover a person’s brain and spinal cord.
It is associated with high death rates and with disability in people who survive. Corticosteroids have been used as an adjunct to
antituberculous drugs to treat people with tuberculous meningitis, but their role has been controversial.
Objectives
To evaluate the effects of corticosteroids as an adjunct to antituberculous treatment on death and severe disability in people with
tuberculous meningitis.
Search methods
We searched theCochrane InfectiousDiseasesGroupSpecializedRegister up to the 18March 2016;CENTRAL;MEDLINE;EMBASE;
LILACS; and Current Controlled Trials. We also contacted researchers and organizations working in the field, and checked reference
lists.
Selection criteria
Randomized controlled trials that compared corticosteroid plus antituberculous treatment with antituberculous treatment alone in
people with clinically diagnosed tuberculous meningitis and included death or disability as outcome measures.
Data collection and analysis
We independently assessed search results and methodological quality, and extracted data from the included trials. We analysed the data
using risk ratios (RR) with 95% confidence intervals (CIs) and used a fixed-effect model. We performed an intention-to-treat analysis,
where we included all participants randomized to treatment in the denominator. This analysis assumes that all participants who were
lost to follow-up have good outcomes. We carried out a sensitivity analysis to explore the impact of the missing data.
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Main results
Nine trials that included 1337 participants (with 469 deaths) met the inclusion criteria.
At follow-up from three to 18 months, steroids reduce deaths by almost one quarter (RR 0.75, 95% CI 0.65 to 0.87; nine trials, 1337
participants, high quality evidence). Disabling neurological deficit is not common in survivors, and steroids may have little or no effect
on this outcome (RR 0.92, 95% CI 0.71 to 1.20; eight trials, 1314 participants, low quality evidence). There was no difference between
groups in the incidence of adverse events, which included gastrointestinal bleeding, invasive bacterial infections, hyperglycaemia, and
liver dysfunction.
One trial followed up participants for five years. The effect on death was no longer apparent at this time-point (RR 0.93, 95% CI 0.78
to 1.12; one trial, 545 participants, moderate quality evidence); and there was no difference in disabling neurological deficit detected
(RR 0.91, 95% CI 0.49 to 1.69; one trial, 545 participants, low quality evidence).
One trial included human immunodeficiency virus (HIV)-positive people. The stratified analysis by HIV status in this trial showed no
heterogeneity, with point estimates for death (RR 0.90, 95% CI 0.67 to 1.20; one trial, 98 participants) and disability (RR 1.23, 95%
CI 0.08 to 19.07; one trial, 98 participants) similar to HIV-negative participants in the same trial.
Authors’ conclusions
Corticosteroids reduce mortality from tuberculous meningitis, at least in the short term.
Corticosteroids may have no effect on the number of people who survive tuberculous meningitis with disabling neurological deficit,
but this outcome is less common than death, and the CI for the relative effect includes possible harm. However, this small possible
harm is unlikely to be quantitatively important when compared to the reduction in mortality.
The number of HIV-positive people included in the review is small, so we are not sure if the benefits in terms of reduced mortality are
preserved in this group of patients.
P L A I N L A N G U A G E S U M M A R Y
Corticosteroids for managing people with tuberculous meningitis
What is tuberculous meningitis and how might corticosteroids work?
Tuberculous meningitis is a serious form of tuberculosis that affects themeninges that cover the brain and spinal cord, causing headache,
coma and death. The clinical outcome is often poor even when people with tuberculous meningitis are treated with antituberculous
drugs.
Corticosteroids are commonly used in addition to antituberculous drugs for treating people with the condition. These drugs help
reduce inflammation of the surface of the brain and associated blood vessels, and are thought to decrease pressure inside the brain,
and thus reduce the risk of death. Some clinicians are concerned that corticosteroids may improve survival, but result in more severely
disabled survivors.
What the evidence shows
We examined the evidence published up to 18 March 2016 and included nine trials with 1337 people that evaluated either dexametha-
sone, methylprednisolone, or prednisolone given in addition to antituberculous drugs; one trial was of high quality, while the other
trials had uncertainties over study quality due to incomplete reporting.
The analysis shows that corticosteroids reduce the risk of death by a quarter at two months to two years after treatment was started (high
quality evidence). Corticosteroids make little or no difference to the number of people who survive TB meningitis with brain damage
causing disability (low quality evidence); because this event is uncommon, even taking the most pessimistic estimate from the analysis
of a slight increased risk with corticosteroids means this would not be quantitatively important when compared to the reduction in
deaths.
One trial followed up participants for five years, by which time there was no difference in the effect on death between the two groups,
although the reason for this change over time is unknown.
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Only one trial evaluated the effects of corticosteroids in human immunodeficiency virus (HIV)-positive people but the number is small
so we are not sure if the benefits in terms of fewer deaths are preserved in this group of patients.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Any corticosteroid compared to control for tuberculous meningitis
Participant or population: adults or children with tuberculous meningit is on tuberculosis (TB) chemotherapy
Settings: hospital care
Intervention: any cort icosteroid
Comparison: placebo or no cort icosteroid
Outcomes Illustrative comparative risks (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk* Corresponding risk
Control Corticosteroid
Follow-up to 2 to 24 months
Death 41 per 100 31 per 100
(27 to 36)
RR 0.75
(0.65 to 0.87)
1337
(9 trials)
⊕⊕⊕⊕
high1,2,3,4,5
Disabling neurological
def icit
8 per 100 7 per 100
(6 to 10)
RR 0.92
(0.71 to 1.20)
1314
(8 trials)
⊕⊕©©6,7,8
low
Follow-up to 5 years
Death 47 per 100 44 per 100
(37 to 53)
RR 0.93
(0.78 to 1.12)
545 part icipants
(1 trial)
⊕⊕⊕©9,10
moderate
Disabling neurological
def icit
15 per 100 14 per 100
(7 to 25)
RR 0.91
(0.49 to 1.69)
244
(1 trial)
⊕©©©10,11,12
very low
* The assumed risk is f rom the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and
the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io; TB: tuberculosis.
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GRADE Working Group grades of evidence.
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Not downgraded for risk of bias. There are few uncertaint ies regarding allocat ion concealment or sequence generat ion in
one of the two largest studies, but the largest trial was high quality and ef fects between these two trials were consistent.
2Not downgraded for inconsistency: low stat ist ical heterogeneity, and the forest plot shows a consistent benef it .
3Not downgraded for indirectness in relat ion to age: all the part icipants in Schoeman 1997 and 59% of the part icipants in
Girgis 1991 were children, and the ef fect is consistent with the other large trial, Thwaites 2004, which included part icipants
aged 14 and over.
4Not downgraded for indirectness for HIV status: one trial included 98 HIV-posit ive part icipants, with no obvious qualitat ive
heterogeneity when compared to HIV-negat ive part icipants (Thwaites 2004). If making recommendations for HIV-posit ive
part icipants only, a guidelines panel may wish to downgrade on indirectness.
5Not downgraded for serious imprecision: the overall meta-analysis is adequately powered to detect this ef fect, but is only
adequately powered when the trials at unclear or high risk of bias are included. The ef fect is clinically important.
6Downgraded by one for risk of bias: four of the eight trials were at high risk of bias due to lack of blinding of outcome
assessors, which could impact on the interpretat ion of assessments of disability.
7Not downgraded for indirectness: trials included children, adults, some HIV-posit ive people, and people f rom dif ferent
cont inents.
8Downgraded by one for imprecision: ef fects range f rom clinically important benef its of 29% reduct ion to 20% increase in
disability.
9Not downgraded on risk of bias or imprecision: number of part icipants followed up was high: 91% at f ive years.
10Downgraded by one for indirectness. This was a single trial conducted in a high quality health care unit in a populat ion with
high levels of infect ious diseases endemicity and poverty. The attenuat ion of the ef fect may be less marked in populat ions
with lower exposure to infect ious diseases and other causes of reduced lif e expectancy associated with poverty. The authors
were not able to establish the cause of death in most of the people who died af ter 9 months follow-up, and so it is not possible
to assess whether these deaths were related to tuberculous meningit is or to other causes.
11Not downgraded on risk of bias. Although the assessors were not blind to the allocat ion, and some assessments were
conducted by telephone, the numbers of disabled part icipants in the two groups were the same, and it is unlikely that
systematic bias in the observers is present.
12Downgraded by two for imprecision. There were few events, and the conf idence interval ranges f rom substant ive harms to
substant ive benef its.
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B A C K G R O U N D
Description of the condition
Tuberculousmeningitis is an inflammationof themeninges, which
aremembranes that envelope a person’s brain and the spinal cord. It
is caused by infectionwith one of several mycobacterial species that
belong to the Mycobacterium tuberculosis complex, which are re-
sponsible for tuberculosis (TB) disease. Tuberculous meningitis is
a severe form of TB and accounts for many deaths (Tandon 1988).
It is a form of extrapulmonary TB (that is, TB that occurs outside
the lungs). TheWorldHealthOrganization (WHO) reported that
0.8 million of the 5.4 million new TB cases reported worldwide
in 2013 were extrapulmonary cases (WHO 2014). There is an as-
sociation between extrapulmonary TB and human immunodefi-
ciency virus (HIV) infection, particularly in people with low CD4
cell counts (Naing 2013). It appears that the higher risk of TB
infection in HIV-positive people means that tuberculous menin-
gitis is also more common in this group (Berenguer 1992; Berger
1994).
People with tuberculousmeningitis usually present with headache,
fever, vomiting, altered conscious level, and sometimes convul-
sions. It is diagnosed clinically, with confirmation by microscopy
and culture of cerebral spinal fluid (CSF) or a polymerase chain
reaction (PCR) test. The low sensitivity of the diagnostic tests
currently available presents a particular challenge for clinicians,
especially when treating children and HIV-positive people. Early
diagnosis and prompt treatment are the main determinants of a
good outcome in people with tuberculous meningitis (Thwaites
2013).
The causes of death and disability in tuberculous meningitis are
multifactorial. The main pathological mechanisms are persistent
or progressive raised intracranial pressure with or without hydro-
cephalus, involvement of the optic nerves or optic chiasm leading
to visual deficit, cranial neuropathies, arachnoiditis, and vasculitis
of the cerebral blood vessels leading to stroke. Neurological dis-
ability related to antituberculous treatment may occur due to op-
tic neuritis related to ethambutol or isoniazid, which sometimes
causes permanent loss of vision, or isoniazid-related peripheral
neuropathy.
Tuberculous meningitis can be classified according to its sever-
ity. The British Medical Research Council (MRC) staging system
categorizes patients into three stages (MRC 1948): stage I (mild
cases) for those without altered consciousness or focal neurolog-
ical signs; stage II (moderately advanced cases) for those with al-
tered consciousness who are not comatose and those with moder-
ate neurological deficits (for example, single cranial nerve palsies,
paraparesis, and hemiparesis); and stage III (severe cases) for co-
matose patients and those with multiple cranial nerve palsies, and
hemiplegia or paraplegia, or both.
Description of the intervention
Without anti-tuberculous treatment, people with tuberculous
meningitis die (Tandon 1988; Thwaites 2002). Streptomycin, one
of the earliest antituberculous drugs to be introduced, reportedly
reduced the case-fatality rate to 63% (Parsons 1988). Newer an-
tituberculous drugs − isoniazid, rifampicin, pyrazinamide, and
ethambutol − are associated with better survival, but mortality
remains comparatively high. Reports of mortality rates vary from
20% to 32%, and permanent neurological deficits in an addi-
tional 5% to 40% of people who survive tuberculous meningitis
(Ramchandran 1986; Alarcón 1990; Jacobs 1990; Jacobs 1992).
Indirect evidence from animal studies provides a biological basis
for how corticosteroids could be effective (Feldman 1958). They
may decrease inflammation, especially in the subarachnoid space;
reduce cerebral and spinal cord oedema, and intracranial pressure
(Feldman 1958; Parsons 1988); and reduce inflammation of small
blood vessels, and damage due to blood flow slowing to the under-
lying brain tissue. However, corticosteroids could also cause harm
by suppressing the person’s immune system. They may suppress
the symptoms of TB infection but promote an unchecked growth
of the bacteria and an increased bacterial load, and reduce in-
flammation of the meninges, which will then reduce the ability of
drugs to cross the blood-brain barrier and enter the subarachnoid
space. Other adverse effects of corticosteroids include gastroin-
testinal haemorrhage, electrolyte imbalance, hyperglycaemia, hy-
pertension, and increased risk of infections from other pathogens
(D’Arcy-Hart 1950).
The use of adjunctive corticosteroids is not known to result in dis-
ability in tuberculous meningitis, especially when used for short
periods of time as is the case in most clinical trials of this interven-
tion. However, there is concern that although corticosteroids may
save the lives of some people who have severe tuberculous menin-
gitis, theymay not necessarily improve their quality of life, as some
people may survive but be left with a severe disability, rendering
them bed-bound and highly dependent. In other words, if corti-
costeroids increase the survival rate but not disability-free survival,
then corticosteroids might actually increase a person’s suffering.
Why it is important to do this review
Several randomized controlled trials (RCTs) have been conducted
on the effect of corticosteroids in managing people with tubercu-
lous meningitis. The conclusions from these trials, seen individu-
ally, appear inconsistent. One trial, Thwaites 2004, showed that
dexamethasone increases survival rate. However, it also raised two
questions: do people who survive because of dexamethasone ther-
apy tend to be left with severe disability, and are there differential
effects among subgroups of people with different degrees of disease
severity? The editorial that accompanied the trial, Quagliarello
2004, and several letters to the editor in response to this trial
(Marras 2005; Seligman 2005) commented that the trial did not
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have sufficient statistical power to answer these questions.We have
prepared a meta-analysis that synthesizes the results from all avail-
able RCTs to try and provide the necessary power to address these
questions.
O B J E C T I V E S
To evaluate the effects of corticosteroids as an adjunct to antitu-
berculous treatment on death and severe disability in people with
tuberculous meningitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
People of any agewith clinically diagnosed tuberculousmeningitis.
Types of interventions
Intervention
Corticosteroid (hydrocortisone, prednisolone, methyl-
prednisolone, or dexamethasone) given orally, intramuscularly, or
intravenously plus antituberculous treatment.
Control
Antituberculous treatment (same as intervention) with or without
placebo.
Types of outcome measures
Primary outcomes
1. Death.
2. Persisting disabling neurological deficit at the end of follow-
up.
Adverse events
Adverse events as reported by the authors, including upper gas-
trointestinal bleeding, invasive bacterial or fungal infections, and
hyperglycaemia.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We searched the following databases using the search terms and
strategy described in Appendix 1: Cochrane Infectious Diseases
Group Specialized Register (18 March 2016); Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), published in the
Cochrane Library, up to Issue 2, February 2016;MEDLINE (1966
to 18 March 2016); EMBASE (1974 to 18 March 2016); and
LILACS (1982 to 18 March 2016). We also searched Current
Controlled Trials (www.controlled-trials.com; accessed 18 March
2016) using ’tuberculosis’ and ’meningitis’ as search terms.
Searching other resources
Researchers
We contacted the following organizations and individuals work-
ing in the field: delegates at the Vth Annual Conference of Indian
Academy of Neurology,Madras, India, 1997; delegates at the XIII
th Global Joint Meeting of the International Clinical Epidemiol-
ogy Network and Field Epidemiology Training Program, Victoria
Falls, Zimbabwe, 1994; and members of the INDEX-TB Guide-
lines technical advisory committee, New Delhi, India, 2015.
Reference lists
Wealso drewon existing reviews of this topic (Ramchandran 1986;
Jacobs 1990; Geiman 1992), and checked the reference lists of all
the trials identified by the above methods.
Data collection and analysis
For selection of studies and data extraction, we independently
conducted each step, and examined agreement between the review
authors. We resolved any disagreements through discussion.
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Selection of studies
We independently screened the search results and retrieved the
full-text articles of all potentially relevant trials.We examined each
trial report to ensure that we included multiple publications from
the same trial only once.We contacted trial authors for clarification
if a trial’s eligibility was unclear. We resolved any disagreements
through discussion and listed the excluded studies and the reasons
for their exclusion.
One of the review authors, KP, conducted one of the included trials
(Prasad 2006), which was started at the same time as Prasad 2000
(the first edition of this Cochrane Review). As ofMarch 2016, this
trial had not been published, but the unpublished data is included
in this review. KP is also a co-author on Kumarvelu 1994. For
both of these studies, HR performed the description of studies,
’Risk of bias’ assessments, data extraction, and interpretation in
consultation with the CIDG Co-ordinating Editor, Paul Garner.
Data extraction and management
We independently extracted data on participant characteristics,
diagnostic criteria, disease severity, HIV status, antituberculous
drug regimen, corticosteroid regimen, and outcome measures us-
ing a pre-piloted data extraction form. We resolved disagreements
through discussion and contacted the corresponding trial author
in the case of unclear or missing data. We contacted the authors
of Lardizabal 1998 to determine the number of deaths in partici-
pants with stage II and III disease, and also the authors of Thwaites
2004 to determine the number of deaths in the five-year follow-
up study (Török 2011).
For dichotomous outcomes, we recorded the number of partici-
pants that experienced the event and the number of participants
randomized to each treatment group, and used them in the anal-
ysis. We also recorded number of participants analysed in each
treatment arm, and used the discrepancy between the figures to
calculate the number of participants lost to follow-up. These fig-
ures allowed us to perform a worst-case scenario analysis to inves-
tigate the effect of missing data.
Assessment of risk of bias in included studies
We independently assessed methodological quality using the
Cochrane ’Risk of bias’ tool and reported the results in a ’Risk
of bias’ table (Higgins 2011). Regarding generation of allocation
sequence and allocation concealment, we classified each of these
as either adequate, inadequate, or unclear according to Jüni 2001.
We reported who was blinded in each trial, and assessed the risk of
bias associated with blinding separately for the two primary out-
comes. If at least 90% of participants were followed up to the trial’s
completion we classified inclusion of all randomized participants
as adequate; otherwise we classified inclusion as inadequate. We
attempted to contact the trial authors if this information was not
specified or if it was unclear. We resolved any disagreements by
discussion between the review authors.
Measures of treatment effect
Weused relative risk as themeasure of treatment effect for analysis.
Unit of analysis issues
There were no cluster RCTs.
Dealing with missing data
The primary analysis is an intention-to-treat analysis where all
participants randomized to treatment are included in the denom-
inator. This analysis assumes that all losses to follow-up have good
outcomes. We carried out a sensitivity analysis to explore the im-
pact of the missing data on the summary effect estimate for death.
Assessment of heterogeneity
We assessed heterogeneity by visually inspecting the forest plots to
determine closeness of point estimates with each other and overlap
of confidence intervals (CIs). We used the Chi² test with a P value
of 0.10 to indicate statistical significance, and the I² statistic to as-
sess heterogeneity with a value of 50% taken to indicate statistical
heterogeneity. We planned to investigate heterogeneity through
the following subgroup analyses: drug resistance (susceptible ver-
sus resistant M. tuberculosis); severity of illness (MRC stages I, II,
and III); and HIV status (seropositive versus seronegative).
Assessment of reporting biases
We conducted visual inspection of the funnel plot of the trials for
any obvious asymmetry that could be evidence of publication bias.
Data synthesis
We analysed the data using Review Manager (RevMan) (RevMan
2014). In view of the absence of significant heterogeneity we de-
cided to perform a meta-analysis. We used risk ratios (RR) with
95% CIs and the fixed-effect model. We summarized the adverse
event data in tables and performed meta-analysis for four types
of treatment-related adverse event: gastrointestinal bleeding, hy-
perglycaemia/glycosuria, invasive bacterial infection (all of which
could be related to corticosteroid use), and hepatitis (related to
antituberculous treatment).We were unable to calculate rate ratios
or summary rate ratios because the person-time over which these
events were observed was unavailable.
Subgroup analysis and investigation of heterogeneity
There was no significant heterogeneity to indicate investigation of
its potential sources.
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Sensitivity analysis
To explore the possible effect of losses to follow-up on the ef-
fect estimate for the outcome death, we performed a worst case
scenario analysis and compared it with an available case analysis.
We assumed all participants who had dropped out of the corti-
costeroid group had an unfavourable outcome whereas those who
had dropped out of the control group had a favourable outcome,
and compared these results to an available case analysis.
R E S U L T S
Description of studies
We included nine trials and excluded 18 trials (Figure 1;
Characteristics of included studies; Characteristics of excluded
studies).
Figure 1. Study flow diagram.
Results of the search
The original version of this Cochrane Review, Prasad 2000, in-
cluded six trials with 595 participants (574 with follow-up, 215
deaths).
The 2008 update, Prasad 2008, added one new trial with 545
participants (535 with follow-up, 199 deaths).
In this update, we included two additional trials: Malhotra 2009
with 97 participants and Prasad 2006 with 87 participants, as well
as follow-updata fromapreviously included trial (Thwaites 2004).
Included studies
We have provided a description of the included RCTs in Table 1.
Geographical location and time period
The included trials were conducted in different time periods (one
in the 1960s, one in the 1980s, four in the 1990s, and two be-
tween 2001 and 2007) and in different geographical regions: Thai-
land (Chotmongkol 1996); Egypt (Girgis 1991); India (O’Toole
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1969; Kumarvelu 1994; Prasad 2006; Malhotra 2009); Philip-
pines (Lardizabal 1998); South Africa (Schoeman1997); andViet-
nam (Thwaites 2004).
Participants
All participants were enrolled on the basis of clinical diagnosis
of probable tuberculous meningitis. All included trials attempted
to confirm the diagnosis by microbiological tests, but only Girgis
1991 reported the outcomes for culture-confirmed cases sepa-
rately. We have described the diagnostic criteria used in each in-
cluded trial in Table 2.
The trials included young children (Schoeman 1997) or adults (
Kumarvelu 1994; Chotmongkol 1996; Lardizabal 1998; Thwaites
2004; Prasad 2006), or both (O’Toole 1969; Girgis 1991), and
both sexes. All trials used the British Medical Research Council
(MRC) system, MRC 1948, to assess baseline severity; two tri-
als included only participants with stage II and III tuberculous
meningitis (Schoeman 1997; Lardizabal 1998), while the other
trials included participants with all stages of severity. Thwaites
2004 specifically reported the inclusion ofHIV-positive andHIV-
negative people, while Chotmongkol 1996 and Malhotra 2009
specifically reported excluding HIV-positive people.
Only Thwaites 2004 reported on drug resistance. In this trial,
M. tuberculosis was cultured from the cerebrospinal fluid (CSF)
or another site in 170 participants (31.2%), 85 from each group.
M. tuberculosis isolates were tested for susceptibility to isoniazid,
rifampicin, pyrazinamide, ethambutol, and streptomycin. Of 170
isolates, 99 (58.2%) were susceptible to all first-line drugs (51
in the placebo group and 48 in the dexamethasone group); 60
(35.3%) were resistant to streptomycin, isoniazid, or both (29 in
the placebo group and 31 in the dexamethasone group); one was
resistant to rifampicin alone (in the dexamethasone group); and
10 (5.9%) were resistant to at least isoniazid and rifampicin (three
in the placebo group and seven in the dexamethasone group).
Interventions
Six included trials used the corticosteroid dexamethasone and two
trials used prednisolone (Chotmongkol 1996; Schoeman 1997).
One trial, Malhotra 2009, compared both dexamethasone and
methylprednisolone with placebo. We have described the dose
regimens of corticosteroids used in Table 3.
Eight trials used three- or four-drug antituberculous regimens.
O’Toole 1969, the earliest trial, used a two-drug regimen consist-
ing of isoniazid and streptomycin.
Duration of antituberculous treatment varied from six months
(Chotmongkol 1996; Schoeman 1997), nine months (Thwaites
2004; Prasad 2006; Malhotra 2009), 12 months (Kumarvelu
1994; Lardizabal 1998), to 24 months (Girgis 1991). In one trial,
O’Toole 1969, the duration of antituberculous treatment was un-
clear.
Follow-up
Seven trials clearly described the follow-up period: two months
(Lardizabal 1998); three months (Kumarvelu 1994); six months
(Schoeman 1997); nine months (Thwaites 2004); 10 months (
Malhotra 2009); two years (Girgis 1991); and 16 to 45 months
(Chotmongkol 1996). It was unclear in O’Toole 1969 and Prasad
2006.
Thwaites 2004 followed up participants over a five-year period,
and reported the results separately in Török 2011.
Outcome measures
All nine trials reported death.
All but one trial reported on disabling neurological deficit in some
way, although there was substantial variation in methods of as-
sessment of this outcome between the trials (O’Toole 1969). We
accepted the trial authors’ definition of disability and, for the pur-
pose of analysis, classified residual deficits into disabling or non-
disabling (as shown in Table 4).
Five trials mentioned adverse events. The trials reported on a num-
ber of other immediate outcome measures we had not considered
in this Cochrane review (see ’Characteristics of included studies’
section).
Excluded studies
We have listed the reasons for excluding 18 studies in the
’Characteristics of excluded studies’ section.
Risk of bias in included studies
See the’Characteristics of included studies’ section, which includes
a ’Risk of bias’ table for each included trial. We have summarized
the results of the ’Risk of bias’ assessments across all included trials
in Figure 2 and Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included trials.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included trial.
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Allocation
Five included trials reported adequate methods of randomization
using either computer generated sequences of random numbers or
random number tables (Girgis 1991; Kumarvelu 1994; Thwaites
2004; Prasad 2006;Malhotra 2009). The remaining included trials
did not clearly report the method of randomization.
We assessed four trials (O’Toole 1969; Chotmongkol 1996;
Thwaites 2004; Prasad 2006) as having adequate allocation con-
cealment, with participants allocated coded treatment packs. The
remaining trials did not clearly describe allocation concealment.
Chotmongkol 1996 reported an imbalance in the severity of dis-
ease between the two groups, with the placebo group having a
greater number of cases with Grade I disease and the steroid group
having a greater number with Grade III disease. MRC stage 3 dis-
ease was present in 6/29 participants (20.7%) in the prednisolone
group, but 4/30 participants (13.3%) in the placebo group. Con-
versely, stage 1 disease was present in 3/29 participants (10.3%)
in the prednisolone group, but 6/30 participants (20%) in the
placebo group. Both favoured the placebo group.
Blinding
Four included trials had adequate blinding of participants and
personnel (O’Toole 1969; Chotmongkol 1996; Thwaites 2004;
Prasad 2006). Participants and personnel were not blinded in the
remaining trials.
We evaluated the blinding of outcome assessors separately for the
two primary outcome measures.
For death, we assessed all included trials as at low risk of bias,
apart from Girgis 1991. We considered that all-cause death was
unlikely to be affected by risk of bias relating to outcome assess-
ment, and therefore we assessed included trials as at low risk of
bias regardless of blinding of outcome assessors for this outcome.
We assessed Girgis 1991 as having unclear risk of bias because
this trial reported death as a case fatality rate, meaning that death
was attributed specifically to tuberculous meningitis. The effect of
misclassification of deaths as being due to tuberculous meningitis
when theywere in fact due to another cause on the overall estimate
of mortality is unknown.
For disabling neurological deficit, we categorized unblinded out-
come assessments as high risk, given the subjectivity of such as-
sessments. Two trials blinded assessors of neurological disability
and were assessed as low risk of bias (Schoeman 1997; Thwaites
2004); and two trials had unblinded outcome assessors and were
assessed as high risk of bias (Kumarvelu 1994; Malhotra 2009).
Incomplete outcome data
Four trials included over 90% of their randomized participants
in the analysis (Lardizabal 1998; Malhotra 2009; O’Toole 1969;
Thwaites 2004), and we assessed these trials as at low risk of bias.
Kumarvelu 1994 included 87.24%of the participants after six par-
ticipants were lost to follow-up (4/24 in the corticosteroid group
and 2/23 in the control group), and did not report on the reasons
participants were lost to follow-up. We therefore assessed this trial
as high risk of bias.
Four trials did not report losses to follow-up (Girgis 1991;
Chotmongkol 1996; Schoeman 1997; Prasad 2006). We assessed
these trials as at unclear risk of bias.
Selective reporting
For two included trials we had access to a trial protocol (Thwaites
2004; Prasad 2006). We assessed Thwaites 2004 as at low risk of
bias as the trial authors reported on all outcomes stated in the
protocol in full. We assessed Prasad 2006 as at high risk of bias, as
the definitions of the main outcomes were altered in the available
(unpublished) data set, and adverse events were not reported.
Lardizabal 1998; Malhotra 2009 and Schoeman 1997 reported
all outcomes stated in the methods section in the results, so we
assessed them as having low risk of bias. Chotmongkol 1996;
Girgis 1991; Kumarvelu 1994 and O’Toole 1969 did not state the
outcome measures in the results, so we assessed them as having
unclear risk of reporting bias.
Other potential sources of bias
All included trials based the inclusion of participants on a clinical
diagnosis of tuberculous meningitis, due to the limitations of mi-
crobiological tests to confirm the diagnosis. This means that the
trials may have included some non-tuberculous meningitis cases.
The direction of bias caused by such inclusions is not likely to
favour corticosteroids.
Effects of interventions
See: Summary of findings for the main comparison Any
corticosteroid compared to control for tuberculous meningitis
Comparison: any corticosteroid versus control
Death
All nine included trials reported on death (Figure 4). The two
largest trials, Girgis 1991 and Thwaites 2004, had more than 150
deaths in each, and the remaining trials were small trials with
fewer deaths. Overall, the direction of effect indicated a benefit of
steroids, with no statistical heterogeneity: the I² statistic was 0%.
13Corticosteroids for managing tuberculous meningitis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 4. Forest plot of comparison: 1 Any corticosteroid versus control, outcome: 1.1 Death.
The pooled analysis found that there were 25% fewer deaths with
corticosteroids (RR 0.75, 95% CI 0.65 to 0.87; nine trials, 1337
participants, Analysis 1.1). The median death rate across trials was
41% without corticosteroids, which translates to a 10% absolute
risk reductionwith corticosteroids when applying this relative risk.
This summary estimate of effect was deemed to be high quality
evidence using the GRADE approach (see Summary of findings
for the main comparison).
Disabling neurological deficit
Eight trials reported on disabling neurological deficit (Figure 5). In
both the intervention and control groups there were fewer events
compared with death, and there was no difference between the two
groups detected at two to 24 months follow-up (RR 0.92, 95%
CI 0.71 to 1.20; eight trials, 1314 participants, Analysis 1.2). This
summary estimate of effect was deemed to be low quality using
the GRADE approach, because half the trials were at high risk of
bias due to lack of blinding of outcome assessors and the estimate
was imprecise.
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Figure 5. Forest plot of comparison: 1 Any corticosteroid versus control, outcome: 1.2 Disabling
neurological deficit.
Death or disabling neurological deficit - combined outcome
Eight trials reported data from which we could derive a combined
outcome incorporating death and disabling neurological deficit
(Chotmongkol 1996; Girgis 1991; Kumarvelu 1994; Lardizabal
1998; Malhotra 2009; Prasad 2006; Schoeman 1997; Thwaites
2004). For this outcome, the overall estimate showed a reduction
in the risk of death or disabling residual neurological deficit with
corticosteroids (RR 0.80, 95% CI 0.72 to 0.89; eight trials, 1314
participants, Analysis 1.3). This effect mirrors the results of the
mortality analysis which is the main contributor of events.
Outcome at five years
Only one recently published trial, Thwaites 2004, reported the
long-term outcome of people with tuberculous meningitis ran-
domized to receive either dexamethasone or placebo. The primary
long-term outcome was survival during the five years follow-up,
while secondary outcomes were status of disability and TB re-
lapse. Fifty participants (9.4%) were lost to follow-up by the end
of the follow-up period. The participants in the dexamethasone
arm fared better on two-year survival rate (0.63 versus 0.55; risk
difference 0.8, 95% CI 0.00 to 0.16; P = 0.07), but this advan-
tage was lost at five years (0.54 versus 0.51; risk difference 0.03,
95% CI −0.06 to 0.12; P = 0.51). Analysis of hazard ratios by
stage of disease at presentation suggested that benefit of dexam-
ethasone inMRC stage I disease tended to persist longer with five-
year probability of survival being 0.69 versus 0.55 (risk difference
0.14, 95%CI−0.01 to 0.29; P = 0.07). However, the test of inter-
action between disease severity and effect size was not statistically
significant (P = 0.46 for zero to three months and P = 0.18 after
three months). For disability, the follow-up study reported similar
numbers with severe persistent neurological disability in both the
steroid and non-steroid groups.
Adverse events
Of the six included trials that mentioned adverse events (O’Toole
1969; Kumarvelu 1994; Chotmongkol 1996; Schoeman 1997;
Thwaites 2004; Malhotra 2009), three trials reported on inci-
dence (O’Toole 1969; Thwaites 2004; Malhotra 2009; Figure 6).
O’Toole 1969 reported four different adverse events (gastroin-
testinal bleeding, glycosuria, infections, and hypothermia), which
occurred in both groups (Table 5). Thwaites 2004 reported on
several adverse events, which were divided into “severe” and other
events (Table 5). Malhotra 2009 reported incidences of hepatitis,
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anti-epileptic toxicity, gastrointestinal bleeding, and paradoxical
tuberculoma in both groups. Schoeman 1997 had “serious side ef-
fects” as an outcome measure and reported “no serious side effects
of corticosteroid therapy”.
Figure 6. Forest plot of comparison: 1 Any corticosteroid versus control, outcome: 1.4 Adverse events.
Meta-analyses examining gastrointestinal bleeding, hepatitis, hy-
perglycaemia, and invasive bacterial infection did not demonstrate
a difference in the incidence of these events between the corticos-
teroid and placebo groups (Analysis 1.4). However, themeta-anal-
ysis is not sufficiently powered to detect a significant difference in
adverse events between groups, so the results should be interpreted
with caution.
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Subgroup analysis
We explored whether heterogeneity was explained within two
main pre-specified subgroups.
For severity of illness, we stratified the results on death by the
severity of illness (MRC stages I, II, and III) in Figure 7. The effect
of corticosteroids appeared to be consistent across all stages of the
disease although the analysis is relatively underpowered (stage I
RR 0.50, 95% CI 0.29 to 0.85; six trials, 305 participants); stage
II (RR 0.72, 95% CI 0.56 to 0.93; seven trials, 581 participants);
and stage III (RR 0.69, 95% CI 0.54 to 0.88; eight trials, 651
participants, Analysis 2.1).
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Figure 7. Forest plot of comparison: 2 Any corticosteroid versus control: stratified by severity of illness,
outcome: 2.1 Death.
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For HIV status, one trial specifically mentioned that 98 of the
included participants were HIV-positive (Thwaites 2004). Anal-
yses stratifying the outcomes of death and disabling neurological
deficit did not detect any large differences, and so showed no ap-
parent effect of HIV status on the effect estimates, but the analysis
is underpowered (Analysis 3.1; Analysis 3.2; Figure 8).
Figure 8. Forest plot of comparison: 3 Any corticosteroid versus control: stratified by HIV status, outcome:
3.1 Death.
Sensitivity analysis
Six trials reported on losses to follow-up (Kumarvelu 1994;
Lardizabal 1998;Malhotra 2009; O’Toole 1969; Schoeman 1997;
Thwaites 2004), with two trials reporting no losses to follow-up
(Lardizabal 1998; O’Toole 1969). We performed a worst case sce-
nario analysis, assuming that all participants lost to follow-up in
the corticosteroid group died while those in the control group
survived (Analysis 4.1). Under this extreme assumption, there was
still a reduction in deaths with corticosteroids (RR 0.80, 95% CI
0.66 to 0.96), and the estimate was similar to the available case
analysis (RR0.71, 95%CI 0.59 to 0.86). Thus, losses to follow-up
are unlikely to have introduced bias in favour of corticosteroids.
Assessment of reporting biases
Six included trials date to the period when registry of clinical
trials was not mandatory or routine. Protocols of the included
trials were unavailable except for two trials (Prasad 2006; Thwaites
2004). For five trials where the outcomes were not clearly specified
in the methods section, we assessed the risk of reporting bias as
unclear. We assessed three trials as at low risk of reporting bias as
all outcomes specified in the protocol or methods were reported
(Schoeman 1997; Thwaites 2004; Malhotra 2009). We assessed
one trial as at high risk of bias, as outcomedefinitionswere changed
in the reported data (unpublished), and adverse events were not
reported (Prasad 2006). Overall, the main analysis is unlikely to
have been affected by reporting bias.
Publication bias
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We have presented a funnel plot of the included trials in Figure
9. It refers to the outcome death and values below one favour
corticosteroids. There is no obvious evidence of publication bias,
but the number of included trials was low.
Figure 9. Funnel plot of risk ratio (RR) from the included trials with the log of their standard error (SE)
values.
D I S C U S S I O N
Summary of main results
See ’Summary of findings’ table 1 (Summary of findings for the
main comparison).
Nine trials met the inclusion criteria. At follow-up from 2 to 24
months, steroids reduce deaths by one quarter. Disabling neuro-
logical deficit is less common in survivors, and steroids may have
little or no effect on this outcome; even taking the upper confi-
dence limit of 20% increased risk, this is probably not quantita-
tively important when compared to the reduced mortality. There
was no difference between groups in the incidence of adverse
events, which included gastrointestinal bleeding, invasive bacterial
infections, hyperglycaemia and hepatitis, although adverse events
were not reported in all studies.
One trial followed up participants for five years. The effect on
death and was no longer apparent at this time-point, and there
was no difference in disabling neurological deficit detected.
One trial included human immunodeficiency virus (HIV)-pos-
itive people. The stratified analysis by HIV status in this trial
showed no heterogeneity, with point estimates for death similar to
HIV-negative participants in the same trial.
Overall completeness and applicability of
evidence
The trials included male and female children and adults, most
of whom were HIV-negative. Thwaites 2004 reported that they
included 98 HIV-positive participants, but they did not stratify
the randomization for this subgroup; therefore the results for this
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subgroup should be interpreted with caution. The effect of cor-
ticosteroids was not significantly different between HIV-positive
and HIV-negative participants, but the trial lacked the power to
detect such a difference if one did exist due to the low number of
HIV-positive participants.
Though the included trials varied in their use of bacteriological
confirmation of diagnosis, there is reasonable evidence to suggest
that the trial participants had tuberculous meningitis. Moreover,
the intention-to-treat analysis in clinically diagnosed participants
provides assurance that use of corticosteroids on the basis of clini-
cal diagnosis doesmore good than harm. This is important because
the decision to use corticosteroids is usually taken on a purely clin-
ical basis when culture reports are unavailable and it is the balance
of benefit and risk of such a decision that needs to be determined
to set a clinical policy. The proportion of confirmed cases is men-
tioned only to provide confidence in the clinical diagnosis made
by the investigators. Separate analysis of culture-positive cases is
probably less relevant for clinical decision making.
All included trials were conducted in high TB burden settings, in
specialist referral hospitals.
Quality of the evidence
Weused theGRADE approach to assess the quality of the evidence
for the two primary outcomes at two to 24 months follow-up,
and at five years follow-up (Summary of findings for the main
comparison).
We graded the quality of the estimate of effect for the outcome
death at two to 24 months follow-up as high. We assessed the
estimate of effect as being at low risk of bias, as while there are
some included trials that did not clearly report on the randomiza-
tion method or allocation concealment, or both, the two largest
included trials had few concerns and showed a consistent effect.
The trials provided evidence of benefit for all age groups. Although
only one trial reported on outcomes for people living with HIV,
there was no obvious qualitative heterogeneity. We did not find
any serious imprecision. We graded the estimate of effect for death
at five years follow-up as moderate, and downgraded by one for
indirectness as the data came from a single trial conducted in a
high quality healthcare unit in a settingwith high levels of endemic
infectious diseases and poverty.
We assessed the quality of the estimate of effect for the outcome
disabling neurological deficit as low quality. The lack of blinding
of outcome assessors of disabling neurological deficit in four of
the eight trials reporting this outcome led us to downgrade the
quality of evidence by one for risk of bias. There was imprecision
of this estimate relating to the small number of events, which led
us to downgrade by one. We graded the estimate of effect for
disabling neurological deficit at five years follow-up as very low
quality, and downgraded by one for indirectness as the data was
from a single trial (as for the outcome death, see above) and by
two for imprecision as there were few events and the CI ranged
from substantive harms to substantive benefits of corticosteroids.
Potential biases in the review process
We have attempted to limit bias in the review process. The
Cochrane Infectious Diseases Group Information Specialist con-
ducted the literature search, and it is unlikely that these searches
missed any major trials; however, we cannot rule out the possibil-
ity that we missed some small unpublished trials. The funnel plot
did not assist with this because there were too few included trials.
To limit bias in the trial selection process and data extraction, we
independently examined the search results, determined study se-
lection, and extracted data.
Agreements and disagreements with other
studies or reviews
Several TB guidelines recommend the use of corticosteroids as
an adjunct to treatment of TB meningitis internationally (CDC
2003; BSI 2009; SNHS 2010; NICE 2011).
Questions remain about the mechanism by which corticosteroids
improve clinical outcomes, and advances in understanding of these
mechanisms have led to a suggestion that some people may benefit
from corticosteroids while others do not, and some may even be
adversely affected by steroids (Thwaites 2013). Leukotriene A4
hydrolase (LTA4H) has been implicated in the pathogenesis ofmy-
cobacterial infection through its effect on the equilibrium between
pro- and anti-inflammatory eicosanoids. Tobin et al. showed that
both low- and high-LTA4H expression zebrafish morphants show
increased mycobacterial bacterial burden compared with wildtype
controls (Tobin 2010; Tobin 2012). Low-LTA4H expression led
to increased lipoxin A4 production and dampening of the early
tissue necrosis factor-alpha (TNF-α) response, and high-LTA4H
morphants showed increased macrophage lysis despite early con-
trol of intracellularmycobacterial replication byTNF-α, with sub-
sequent extracellular mycobacterial growth. Both of these states
led to uncontrolled mycobacterial replication. Thus, hypersuscep-
tibility to mycobacterial infection is associated with both inade-
quate and excessive inflammatory responses.
The use of dexamethasone in the zebrafish morphants rescued
high-LTA4H animals but led to increased susceptibility in low-
LTA4H animals (Tobin 2012). In people, the LTA4H transcrip-
tion level is regulated by a polymorphism in the gene promoter
at SNP rs17525495, with rs17525495 TT associated with high
LTA4H protein expression, rs17525495 CC associated with low
expression, and rs17525495 CT intermediate expression. Geno-
typing performed on 182 participants from a series of clinical
studies in Vietnam demonstrated that people with the TT geno-
type (high LTA4H, hyperinflammatory) had the highest mortal-
ity amongst participants who did not receive dexamethasone, but
the lowest in the dexamethasone group; the people with the CC
genotype (low LTA4H, hypoinflammatory) had the highest mor-
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tality in the dexamethasone group (Tobin 2012). These results
suggest that LTA4H genotype may have an important influence
on whether or not steroids are effective in tuberculous meningitis,
at least in this population.
Further investigation into the relationship betweenLTA4Hexpres-
sion in people, dexamethasone use, and outcomes in people with
TBmeningitis is needed to determine whether dexamethasone use
is associated with harm in the subset of people with LTA4H defi-
ciency, and whether genotyping people for LTA4H at diagnosis is
useful to guide treatment with corticosteroids. Other drugs that
target parts of this inflammatory pathway, such as thalidomide,
adulimumab and infliximab, have been used as rescue therapy
in people with severe inflammatory complications of TB menin-
gitis, but few clinical trials have been conducted on the use of
these agents, and all these potent immunosuppressive drugs have
the potential to cause harm as well as benefit (Schoeman 2001;
Schoeman 2004; Schoeman 2010; Jorge 2012; Lee 2012; Molton
2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is high quality evidence of the benefit of corticosteroids in
preventing death in people with tuberculous meningitis. This ef-
fect is probably attenuated over time, as five-year follow-up data
from one trial suggests this, but there may be confounding fac-
tors leading to this observation. Corticosteroids appear to reduce
mortality in people with TB meningitis, regardless of the British
Medical Research Council (MRC) stage at presentation. Corticos-
teroids may have no effect on rates of disabling neurological deficit
in people who survive TB meningitis, but the confidence inter-
val around this estimate includes increased risk of this outcome.
However, given the benefit associated with reduced risk of death,
this is unlikely to be quantitatively important when considering
whether or not to use corticosteroids in patients with TB menin-
gitis. There is uncertainty about whether or not corticosteroids
are beneficial for HIV-positive people with TB meningitis due to
the lack of direct evidence in this group. Corticosteroids may not
be associated with increased risk of adverse events, but there is
uncertainty related to the limited reporting of adverse events in
the included trials.
Implications for research
Further research is unlikely to add to certainty about the effect
of corticosteroids in people with tuberculous meningitis who are
HIV-negative in preventing death.
In people that are immunosuppressed, such as people living with
HIV, it is unclear whether corticosteroids are of benefit. As corti-
costeroids could lead to greater risk of harm in these people, fur-
ther research would be useful to provide clear guidance for treat-
ment.
Another question that remains unanswered is the optimum choice
of corticosteroid drug and dosing regimen. Given the fact that
use of corticosteroids carries the risk of adverse events, and that
many of these are dose-dependent, further research examining this
question would be beneficial.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chotmongkol 1996
Methods Randomized parallel group study.
Length of follow-up: 6 months but post-study follow-up continued for 16 to 45 months
(mean = 30 months)
Participants Setting: Sringarind Hospital, Khon Kaen, Thailand - tertiary referral centre
Number of participants: 59 participants; 27 females, 32males; 29 received prednisolone,
30 received no steroid
Inclusion criteria: age > 15 years; clinically diagnosed tuberculous meningitis (character-
istic clinical features with typical CSF profile consisting of lymphocytic meningitis with
low glucose level and elevated protein), all stages of disease included
Exclusion criteria: children <15 years old, HIV-positive, VDRL positive for syphilis,
cryptococcal antigen positive, CSF positive for bacterial or fungal infection on latex
agglutination or culture, malignant cells in CSF
HIV status: HIV-positive participants excluded.
Interventions 1. Antituberculous treatment (ATT) plus prednisolone orally on tapering dosage for
5 weeks (week 1 = 60 mg, week 2 = 45 mg, week 3 = 30 mg; week 4 = 20 mg, week 5 =
10 mg).
2. ATT alone.
ATT: isoniazid oral (300 mg), rifampicin oral (600 mg, 450 mg for those weighing <
50 kg), pyrazinamide oral (1500 mg), and streptomycin intramuscular (750 mg) for the
first 2 months; followed by isoniazid and rifampicin in above dosage for 4 months
Outcomes 1. Death at the end of 6 months.
2. Residual neurological deficits at the end of 6 months.
3. Time until resolution of fever.
4. Time until disappearance of headache.
Adverse events recorded were gastrointestinal bleeding and hyperglycaemia
Notes Date: July 1990 to December 1992.
Trialists: Department of Medicine, Khon Kaen University, Thailand; no collaborators
There was baseline prognostic imbalance in favour of placebo group:MRC stage 3 disease
was present in 6/29 (20.7%) in prednisolone group, but 4/30 (13.3%) in placebo group.
Conversely, stage 1 disease was present in 3/29 (10.3%) in prednisolone group, whereas
6/30 (20%) in placebo group. Both favoured the placebo group
Ziehl-Nielsen staining of CSF for AFBs or culture positive for M. tuberculosis, or both,
in 4/29 in the prednisolone group and 1/30 in the placebo group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Block randomization by a block size of 4,
but insufficient information on sequence
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Chotmongkol 1996 (Continued)
generation
Allocation concealment (selection bias) Low risk “Patients were randomised to receive pred-
nisolone or placebo by a block size of four
using coded treatment A and B.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding with use of placebo.
Blinding of outcome assessment (death) Low risk Blinding of outcome assessorswas not spec-
ified, but this is unlikely to introduce bias
for all-cause mortality
Blinding of outcome assessment (disabling
neurological deficit at the end of follow-up)
Unclear risk Blinding of outcome assessorswas not spec-
ified, so impact on assessment of neurolog-
ical deficits during follow-up was unclear
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up were not reported.
Selective reporting (reporting bias) Unclear risk The protocol was unavailable, and out-
comes were not clearly specified in the
methods
Girgis 1991
Methods Randomized parallel group, 2-arm study with allocation ratio: 1:1
Length of follow-up: 24 months.
Participants Setting: Abbassia Fever Hospital, Cairo, Egypt - tertiary referral centre
Number of participants: 280 participants; 158 males, 122 females; 145 received dexam-
ethasone, 135 received no steroid
Age: all ages included, 37% aged 0 to 5 years, 22% aged 5 to 16 years
Inclusion criteria: clinically diagnosed tuberculous meningitis based on history and ex-
amination (duration of illness > 30 days, consisting of fever, headache, vomiting, altered
sensorium, generalized weakness or cranial nerve deficits); comparison of first and second
CSF findings; and a poor response to antibacterial therapy for 48 hrs
Exclusion criteria: not reported.
HIV status: not reported.
Interventions 1. ATT plus dexamethasone given intramuscularly (12 mg/day to adults and 8 mg/
day to children weighing < 25 kg) for 3 weeks and then tapered during the next 3
weeks).
2. ATT alone.
ATT: isoniazid (10 mg/kg/day, maximum 600 mg) intramuscularly for 2 weeks then
orally for 2 years, streptomycin intramuscular (25 mg/kg/day, maximum 1000 mg) for
6 weeks, and ethambutol oral (25 mg/kg/day, maximum 1200 mg) for 6 weeks, then 15
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Girgis 1991 (Continued)
mg/kg/day for 2 years
Outcomes 1. Death during 2-year follow-up.
2. Residual neurological sequelae.
3. Neurological complications developing during therapy.
4. CSF leucocytes, glucose, and protein on day 15 and day 30 after initiation of
treatment.
Trial authors reported case-fatality rate, which by definition includes all deaths caused by
tuberculous meningitis, but not deaths attributed to other causes. They did not report
whether any death during the follow-up period was considered to be due to any cause
other than tuberculous meningitis
Notes Date: 1982 to 1987.
Trialists:United StatesNavalMedical ResearchUnitNo. 3,Cairo, Egypt; no collaborators
160/280 CSF culture positive for M. tuberculosis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Pre-designed 1-to-1 number randomiza-
tion chart.
Allocation concealment (selection bias) Unclear risk Insufficient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No attempt at blinding, but the impact on
mortality is unclear
Blinding of outcome assessment (death) Unclear risk Outcome assessors were not blinded, and
impact on risk of bias for case fatality rate
is unclear as this is a measure of death at-
tributed to tuberculous meningitis only
Blinding of outcome assessment (disabling
neurological deficit at the end of follow-up)
High risk Outcome assessorswere not blinded, so risk
of bias in assessment of neurological deficit
during follow-up is high
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses to follow-up were not reported.
Selective reporting (reporting bias) Unclear risk The protocol was unavailable and out-
comes were not clearly specified in the
methods
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Kumarvelu 1994
Methods Randomized parallel group 2-arm study with allocation ratio 1:1
Length of follow-up: 3 months.
Participants Setting: all India Institute of Medical Sciences (AIIMS), New Delhi, India - tertiary
referral centre
Number of participants: 47 participants; 22 females, 25 males; 24 received dexametha-
sone, 23 received no steroid
Inclusion criteria: aged over 10 years; clinically diagnosed tuberculous meningitis (meet-
ing any 3 of the following criteria)
1. Fever, headache, neck stiffness for 2 weeks.
2. CSF profile of > 20 cells/mm³ predominantly lymphocytes, protein > 1 g/L, and
sugar < 2/3 of corresponding blood sugar with no malignant cells on cytological
examination and bacteria/fungi on culture.
3. Head contrast-enhanced CT showing basal exudates or hydrocephalus.
4. Clinical, radiological, or histological evidence of extracranial TB).
All stages of severity and any duration of disease included.
Exclusion criteria: aged < 10 years, received ATT for more than 4 weeks prior to admis-
sion, received corticosteroids before admission
HIV status: not reported.
Interventions 1. ATT plus dexamethasone (intravenous 16 mg/day in 4 divided doses for 7 days,
then oral tablet 8 mg/day for 21 doses, and in children 0.6 mg/kg/day for 7 days,
reducing to 0.3 mg/kg/day for 21 days).
2. ATT alone.
ATT: rifampicin (450 mg), isoniazid (300 mg), and pyrazinamide (1500 mg) all oral
daily; for those weighing < 30 kg 15 mg/kg, 10 mg/kg, and 30 mg/kg respectively
Duration of treatment: 1 year.
Outcomes 1. Death at 3 months.
2. Major sequelae (totally dependent for activities of daily living) at 3 months.
3. Minor sequelae (activities of daily living with no or minimal assistance) at 3
months.
4. Adverse effects.
5. Time to recover from altered sensorium, from fever, and from headache.
Notes Location: India.
Date: March 1991 to March 1992.
Trialists: Department of Neurology, All India Institute of Medical Sciences, New Delhi,
India; no collaborators
Number of participants that were CSF culture positive for M. tuberculosis was not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Used random numbers from Fisher’s table.
Allocation concealment (selection bias) High risk Not done.
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Kumarvelu 1994 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding but its impact on mortality
remains unclear.
Blinding of outcome assessment (death) Low risk Outcome assessors were not blinded, but
this is unlikely to introduce bias for all-
cause mortality
Blinding of outcome assessment (disabling
neurological deficit at the end of follow-up)
High risk Outcome assessors were not blinded, so the
risk of bias in assessment of neurological
deficit during follow-up is high
Incomplete outcome data (attrition bias)
All outcomes
High risk Six out of 47 participants were lost to fol-
low-up (4 in the treatment arm and 2 in
the control arm)
Selective reporting (reporting bias) Unclear risk Protocol unavailable and outcomes not
clearly specified in the methods
Lardizabal 1998
Methods Randomized parallel group, 2-arm study with allocation ratio 1:1
Length of follow-up: 2 months
Participants Setting: University of the Phillipines College of Medicine, tertiary care facility, single
centre
Number of participants: 58 participants; 31 males and 27 females; 29 received dexam-
ethasone, 29 received no steroid
Inclusion criteria: aged 18 years and above; probable tuberculous meningitis diagnosed
using ASEAN Neurological Association criteria based on the following
1. Insidious onset fever for at least 1 week, headache and vomiting, with or without
nuchal rigidity followed by altered consciousness, cranial nerve palsies, or long tract
signs.
2. CSF profile of lymphocyte predominance, elevated protein and reduced glucose.
3. CSF negative for cryptococcal antigen plus 1 or more of the following: basilar/
meningeal enhancement on contrast CT scanning, active pulmonary disease, positive
purified protein derivative (PPD), history of contact with TB; confirmed tuberculous
meningitis based on positive CSF culture or microscopy, or both.
4. British MRC stages II and III disease.
Exclusion criteria
1. Aged under 18.
2. British MRC stage I TB meningitis, or bacterial or fungal meningitis diagnosed
on CSF culture.
3. Pregnancy or lactation.
4. History of diabetes mellitus or hypertension.
5. Upper gastrointestinal bleeding, or history of peptic ulcer disease in the previous
month.
6. Raised bilirubin, SGPT or serum creatinine.
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Lardizabal 1998 (Continued)
Interventions 1. Antituberculous treatment plus dexamethasone (16 mg/day for 3 weeks (first 5
days intravenous thereafter orally or via nasogastric tube); after 3 weeks corticosteroid
was tapered by 4 mg decrements every 5 days).
2. Antituberculous treatment alone.
Antituberculous treatment: rifampicin (10 to 15 mg/kg/day), isoniazid (5 to 10 mg/kg/
day), pyrazinamide (15 to 30 mg/kg/day), and ethambutol (15 to 20 mg/kg/day) for the
first 2 months; thereafter, rifampicin and isoniazid only for 10 months; total treatment
duration 12 months; route of administration was not stated
An H2-antagonist (famotidine or ranitidine) was given during the period of corticos-
teroid administration
Outcomes 1. Death on days 15, 30, and 60 post-randomization.
2. Functional independence assessed by attending doctor on admission and 60 days
after randomization: Functional Independence Measure (FIM) used assesses self care,
sphincter control, mobility, locomotion, and social cognition on a 7-point scale.
3. Potential adverse reactions to corticosteroids including weakness, oedema,
hypertension, euphoria, psychosis, epigastric discomfort, Cushingoid facies, hirsutism,
acne, insomnia, and increased appetite.
Notes Location: Philippines.
Date: November 1996 to July 1997.
Trialists: University of Philippines, College of Medicine; no collaborators
We contacted the trial authors to determine the number of deaths in participants with
stage II and III disease
Number of participants that were CSF culture positive for M. tuberculosis was not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence was un-
clear.
Allocation concealment (selection bias) Unclear risk Insufficient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding but its impact on mortality
remains unclear.
Blinding of outcome assessment (death) Low risk Outcome assessors were not blinded, but
unlikely to introduce bias for all-causemor-
tality
Blinding of outcome assessment (disabling
neurological deficit at the end of follow-up)
High risk Outcome assessorswere not blinded, so risk
of bias in assessment of neurological deficit
during follow-up is high
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Lardizabal 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up, changes of treat-
ment arm, or withdrawals. Outcomes were
reported for all randomized participants
Selective reporting (reporting bias) Low risk The protocol was unavailable, but all out-
comes specified in the methods section are
reported on in the results
Malhotra 2009
Methods Randomized parallel group 3-arm study with allocation ratio 1:1:1
Length of follow-up: 10 months.
Participants Setting: Chhatrapati Shahuji Maharaj Medical University (CSMMU), Lucknow, India
- tertiary referral centre
Number of participants: 91 participants; 48 males, 43 females (6 participants random-
ized but lost to follow-up); 32 randomized to dexamethasone (1 lost to follow-up), 33
randomized to methylprednisolone (3 lost to follow-up), 32 randomized to no steroid
(2 lost to follow-up)
Inclusion criteria: age > 14 years; meningitic syndrome; tuberculous meningitis defined
as “definite” if acid-fast bacilli were seen in CSF, “probable” if one or more than one of
the following present: suspected active pulmonary TB on chest radiography, acid-fast
bacilli in any specimen other than CSF, clinical evidence of extrapulmonary TB, and
“possible” if at least 4 of the following were present: history of TB, predominance of
lymphocytes in CSF, duration of illness > 5 days, radio of CSF to plasma glucose < 0.5,
altered consciousness, yellow CSF, or focal neurological signs
Exclusion criteria: age < 14 years; HIV-positive; contraindication to corticosteroids;
received corticosteroid or antituberculous drugs before presentation at the CSMMU,
evidence of space occupying lesion on CT brain, refused consent
Interventions 1. ATT + dexamethasone (intravenous for 4 weeks as (at 0.4, 0.3, 0.2 and 0.1 mg/
kg.day during weeks 1, 2, 3, 4 respectively); daily oral dose for following 4 weeks as 4,
3, 2, 1 mg/day on weeks 5, 6, 7, 8 respectively).
2. ATT + methylprednisolone (intravenous for 5 days (1 g/day for participants
weighing > 50kg and 20 mg/kg/day for participant weighing < 50 kg).
3. ATT alone.
ATT: rifampicin (15 mg/kg/day), isoniazid (10 mg/kg/day), pyrazinamide (30 mg/kg/
day) and either ethambutol (20mg/kg/day) or streptomycin (15mg/kg/day) for 2months
and isoniazid (10 mg/kg/day) for 7 months
Outcomes Assessed at 6 months post-randomization.
1. Death or severe disability.
2. Adverse events: hepatitis; anti-epileptic toxicity, gastro-intestinal bleeding,
paradoxical tuberculoma.
3. Deterioration in vision, development of new focal neurological deficit and new-
onset seizures.
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Malhotra 2009 (Continued)
Notes Date: January 2006 to July 2007.
Trialists: CSMMU, Lucknow, Department of Neurology, Uttar Pradesh, India
97/126 acid-fast stain/culture positive forM. tuberculosis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random allocation using computer-gener-
ated randomization sheet
Allocation concealment (selection bias) Unclear risk Insufficient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding, but the impact on mortality
is unclear.
Blinding of outcome assessment (death) Low risk Outcome assessors were not blinded, but
this is unlikely to introduce bias for all cause
mortality
Blinding of outcome assessment (disabling
neurological deficit at the end of follow-up)
High risk Outcome assessors were not blinded, so the
risk of bias in assessment of neurological
deficit during follow-up is high
Incomplete outcome data (attrition bias)
All outcomes
Low risk Six out of 97 participants were lost to fol-
low-up (1 in dexamethasone, 3 in methyl-
prednisolone, and 2 in the control arm)
Selective reporting (reporting bias) Low risk The protocol was unavailable, but all out-
comes specified in the methods were re-
ported
O’Toole 1969
Methods Randomized parallel group 2-arm study with allocation ratio 1:1
Length of follow-up: unclear.
Participants Setting: Infectious Diseases Hospital, Calcutta, India - tertiary referral centre
Number of participants: 23 participants in total, 11 females, 12 males; 11 received
dexamethasone, 12 received no steroid
Inclusion criteria: not explicitly specified, but the trial authors state that due to the trial
institution’s admissions policy only participants with a short history or acute signs and
symptoms of meningitis were selected; due to limited bed availability only moderate to
severely unwell participants were included (MRC Stage II and III). All age groups were
included. Treatment allocation was stratified for age and disease severity
HIV status: not reported.
33Corticosteroids for managing tuberculous meningitis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
O’Toole 1969 (Continued)
Interventions 1. ATT plus dexamethasone given for up to 4 weeks in an adult dose of 9 mg/day
during the first week, 6 mg/day during the second week, 3 mg/day during the third
week, and 1.5 mg/day during the 4th week; dose for children was calculated according
to their body surface area (no more details available).
2. ATT alone.
ATT: isoniazid intramuscular or oral (10 mg/kg/day, except in children < 2 years of age
who received 20 mg/kg/day) and streptomycin (20 mg/kg/day, maximum 1 g), duration
not specified
Outcomes 1. Death at the end of follow-up (duration unclear).
2. Number with elevated CSF opening pressure on days 1, 4, 7, and 14.
3. CSF sugar, protein, and cell count on days 1, 4, 7, 14, 21, and 28 in decreasing
number of participants, depending apparently on the surviving number. Number with
residual deficits not given. Surviving participants all been described as “significantly
improved”.
4. Adverse events recorded: upper gastrointestinal bleed, invasive bacterial infection,
hypoglycaemia, and hypothermia.
5. Resolution of CSF findings.
Notes Date: February 1966 to March 1967.
Trialists: Calcutta School of Tropical Medicine and the Infectious Disease Hospital,
Calcutta, India, in collaboration with Johns Hopkins University, Baltimore, USA
16/23 participants had either smear (2) or culture (9), or both smear and culture (5)
positive for tubercle bacillus; remaining 7 participants had clinical features consistent
with the diagnosis of tuberculous meningitis and CSF profile consisting of elevatedwhite
cell count and protein, decreased glucose, and negative India ink smear for Cryptococcus;
the trial authors intended to include only moderately advanced (stage II) and severe
(stage III) cases, but 1 case of stage I was entered in the treatment group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information.
Allocation concealment (selection bias) Low risk “New admissions to the study were as-
signed their drug bymatching age and stage
of disease then selecting the next unused
coded preparation in that prognostic cate-
gory.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding unlikely to have been broken.
Blinding of outcome assessment (death) Low risk Blinding of outcome assessorswas not spec-
ified, but this was unlikely to introduce bias
34Corticosteroids for managing tuberculous meningitis (Review)
Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
O’Toole 1969 (Continued)
for all-cause mortality
Blinding of outcome assessment (disabling
neurological deficit at the end of follow-up)
Low risk Neurological deficit was not reported on in
this trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes reported in 23/23 partici-
pants.
Selective reporting (reporting bias) Unclear risk The protocol was unavailable and out-
comes not clearly specified in the methods
Prasad 2006
Methods Double-blind, randomized, concurrent placebo-controlled parallel group trial
Length of follow-up: 18 months. A 10-year follow-up was planned, but not completed
Participants Setting: All India Institute ofMedical Sciences, NewDelhi, India - tertiary referral centre
Number of participants: 87 participants; 39 females, 48 males; 41 received dexametha-
sone, 46 received placebo
Inclusion criteria: clinically diagnosed tuberculous meningitis based on meeting these 3
criteria
1. Gradual onset of any 2 of fever, progressive headache, or impaired consciousness
with at least 1 symptom of 3 weeks duration.
2. At least 1 sign of meningeal irritation for example, neck stiffness, Kernig’s sign,
Brudzinski’s sign (except in deeply comatose cases).
3. CSF profile characteristic of tuberculous meningitis (containing more than 0.02 ×
109 cells per litre with predominant lymphocytes , protein more than 1 g/Pl, sugar less
than two-thirds of simultaneous blood sugar).
Exclusion criteria
1. Alternative diagnosis (including non-tubercular infection, malignancy) made on
CSF testing or imaging.
2. Treatment with steroids regularly for more than 10 days used during the current
illness.
3. Liver disease or gout.
4. History of gastric or duodenal ulcer, gastrointestinal haemorrhage, malignant
hypertension.
5. Pregnant women.
HIV status: not specified.
Interventions 1. ATT plus dexamethasone 0.15 mg per kg body weight (up to a maximum of 4
mg) every 6 hours for 3 weeks then tapered gradually.
2. ATT plus placebo (0.9% saline).
ATT: oral (through nasogastric tube in unconscious participants) administration of iso-
niazid 10 mg/kg up to 300 mg, rifampicin 15 mg/kg up to 450 mg, and pyrazinamide
30 mg/kg for participants less than 30 kg and 1500 mg for participants over 30 kg daily,
plus pyridoxine 50 mg daily. Total duration was 9 months
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Prasad 2006 (Continued)
Outcomes Outcomes identified in trial protocol
1. Treatment success, defined as resolution of meningitic symptoms and achievement
of good neurologic function and stability of this state for 3 consecutive months.
2. All-cause death in the first 3 months.
3. Secondary treatment failure.
4. Adverse events related to ATT or dexamethasone, for example deranged liver
function tests, hypertension, hyperglycaemia, secondary infection, rash, gastrointestinal
bleeding.
Outcomes reported in results
1. Death.
2. Non-disabling neurological deficit.
3. Disabling neurological deficit.
4. Bad outcome (death plus disabling neurological deficit).
5. Any deficit (non-disabling neurological deficit plus disabling neurological deficit.
Notes Date: recruitment started February 1996.
Trialists: Department of Neurology, All India Institute of Medical Sciences, New Delhi,
India
We based this trial description and our ’Risk of bias’ assessment on the trial protocol
and unpublished outcome data, including baseline characteristics of participants. As the
final report was unavailable, we could not assess variations between the protocol and the
trial itself
There were 6 losses to follow-up at 18 months follow-up, 3 in each group
Number of participants that were CSF culture positive for M. tuberculosis was not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible consenting subjects will be
randomised using block randomisation
method. A varying block size of 4 and 6will
be used to avoid possible bias in selection
of subjects if preceding ones had noticeable
adverse effects. Patients will be randomised
to either group in 1:1 ratio by statistician
in the biostatistics department.”
Allocation concealment (selection bias) Low risk “Each patient will be assigned a unique
identification number which remained
with him throughout the study and had
a drug code incorporated into it. All the
care givers, outcome evaluators and pa-
tients will be masked to treatment alloca-
tion. Vials containing indistinguishable so-
lutions of either dexamethasone or placebo
(0.9%NaCl) will be prepared, labelled and
distributed by the pharmacist at AIIMS.
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Prasad 2006 (Continued)
Vials will be boxed in sets of thirty (more
than one patient’s requirement) and each
vial will have the same code number as the
box and were identically labelled as con-
taining 5mg dexamethasone sodium phos-
phate per ml. Coding will be done by as-
signing a random set of numbers to the ac-
tive drug and a different set to the placebo.
”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “each vial will have the same code num-
ber as the box and were identically labelled
as containing 5mg dexamethasone sodium
phosphate per ml”
Blinding of outcome assessment (death) Low risk Blinding of outcome assessorswas not spec-
ified, but this was unlikely to introduce bias
for all-cause mortality
Blinding of outcome assessment (disabling
neurological deficit at the end of follow-up)
Unclear risk Outcome assessors and methods of assess-
ment were not clearly described in the pro-
tocol
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The trial profile was not reported, includ-
ing number of participants eligible, and
number of participants excluded. Reasons
for losses to follow-up were not described
Selective reporting (reporting bias) High risk Outcome measures are re-defined in the
reported results. Adverse events and sec-
ondary treatment failure were not reported
Schoeman 1997
Methods Randomized parallel group 2-arm study with allocation ratio 1:1
Length of follow-up: 6 months.
Participants Setting: Tygerberg Hospital, Tygerberg, South Africa.
Number of participants: 141 randomized (gender balance not specified); 70 received
prednisolone and 71 received no steroid
Inclusion criteria: children (age limit not specified); diagnosis of tuberculous meningitis
based on history and “typical CSF changes” with at least 2 of the following: strongly
positive (> 15 mm) Mantoux test, chest x-ray suggesting TB or CT head showing basal
enhancement and acute hydrocephalus. Only MRC Stage II and III included
HIV status: not reported.
Interventions 1. ATT plus prednisolone (given to first 16 participants in a dose of 2 mg/kg/day
and to the remaining 54 participants in a dose of 4 mg/kg/day (once in the morning);
decision to double the dose after the first 16 participants).
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Schoeman 1997 (Continued)
2. ATT alone.
ATT: isoniazid (20 mg/kg/day), rifampicin (20 mg/kg/day), ethionamide (20 mg/kg/
day), and pyrazinamide (40 mg/kg/day) for 6 months
Outcomes 1. Deaths at 6 months.
2. Disability (mild and severe) at 6 months.
3. Serious side effects.
4. Baseline and pulse pressure of lumbar CSF.
5. Changes in ventricular size in CT.
6. Proportion of participants with successful treatment of raised intracranial pressure.
7. Proportion of participants with basal ganglia infarcts, tuberculomas, meningeal
enhancement, and enlarged subarachnoid spaces.
Notes Date: not mentioned.
Trialists: Department of Paediatrics and Child Health, Faculty of Medicine, University
of Stellenbosch and Tygerberg, South Africa, in collaboration with CERSA, Division of
Biostatistics, Medical Research Council, Parow-Valley, South Africa
The decision to double the prednisolone dose was taken when the authors became aware
of a study that showed that rifampicin decreased the bioavailability of prednisolone by
66% and increased the plasma clearance of the drug by 45%; trial authors reported the
outcome of both the dose groups together andmentioned that themortality ormorbidity
between the 2 prednisolone dosage groups did not differ significantly
23/141 CSF culture positive for M. tuberculosis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “patients whose parents gave informed
written consent were randomly allocated to
a steroid or nonsteroid treatment group”
Allocation concealment (selection bias) Unclear risk Insufficient information.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding, but the impact on mortality
is unclear.
Blinding of outcome assessment (death) Low risk Blinding of outcome assessors not speci-
fied, but unlikely to introduce bias for all
cause mortality
Blinding of outcome assessment (disabling
neurological deficit at the end of follow-up)
Low risk Blinding of assessors. “All these individuals
were blinded to the treatment status of the
patients at admission.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Three participants in the steroid group and
4 participants in the nonsteroid group were
not accounted for in the results section.
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Schoeman 1997 (Continued)
Losses to follow-up were not reported, so
the impact on results is unclear
Selective reporting (reporting bias) Low risk The protocol was unavailable, but all pre-
specified outcomes stated in the methods
were reported
Thwaites 2004
Methods Randomized parallel group 2-arm study with allocation ratio 1:1
Length of follow-up: 9 months (initial report), followed by a 5-year follow-up trial
Participants Setting: PhamNgoc ThachHospital for Tuberculosis and LungDisease and theHospital
for Tropical Diseases, Ho Chi Minh City, Vietnam - two tertiary referral centres
Number of participants: 545 randomized, 331 males, 214 females; 274 received dexam-
ethasone, 271 received placebo
Inclusion criteria: aged over 14 years, clinical meningitis (defined as combination of
nuchal rigidity and CSF abnormalities). Tuberculous meningitis defined as “definite”
if acid-fast bacilli were seen in CSF, “probable” if at least 1 of the following present:
suspected active pulmonary TB on chest radiography, acid-fast bacilli in any specimen
other than CSF, clinical evidence of extrapulmonary TB, and “possible” if at least 4
of the following were present: history of TB, predominance of lymphocytes in CSF,
duration of illness more than 5 days, ratio of CSF to plasma glucose less than 0.5, altered
consciousness, yellow CSF, focal neurological signs
Exclusion criteria: contraindication to corticosteroids; received more than 1 dose of any
corticosteroid, or more than 30 days of ATT immediately before the trial
HIV status: 98/545 HIV-positive, 44/274 (16.1%) in dexamethasone group, 54/271
(19.9%) in placebo group. Three participants in the dexamethasone group, and eight
participants in the placebo group were not tested for HIV
Interventions 1. ATT plus dexamethasone, dose stratified by disease severity*.
2. ATT plus placebo.
ATT: For previously untreated participants: oral isoniazid (5 mg/kg), rifampicin (10 mg/
kg), pyrazinamide (25 mg/kg, maximum, 2 g/day), and intramuscular streptomycin (20
mg/kg, maximum 1 g/day) for 3 months followed by 6 months of isoniazid, rifampicin,
and pyrazinamide at the same daily doses; ethambutol (20 mg/kg; maximum 1.2/day)
substituted for streptomycin in HIV-positive participants and was added to the regimen
for 3 months for participants previously treated for TB
*Grade II and III disease: intravenous dexamethasone sodium phosphate given 0.4 mg/
kg/day for week 1, 0.3 mg/kg/d for week 2, 0.2 mg/kg/d for week 3, and 0.1 mg/kg/day
for week 4, and then oral dexamethasone for 4 weeks decreasing by 1 mg each week.
Grade I disease: intravenous dexamethasone sodium phosphate 0.3 mg/kg/day for week
1 and 0.2 mg/kg/day for week 2 followed by 4 weeks of oral dexamethasone (0.1 mg/
kg/day for week 3 then a total of 3 mg/day, decreasing by 1 mg each week)
Outcomes Assessed at 9 months post-randomization.
1. Death or severe disability.
2. Adverse events: hepatitis; gastrointestinal bleeding, bacterial sepsis, septic shock,
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Thwaites 2004 (Continued)
brain herniation syndrome, decreased visual acuity, hyponatraemia, hyperglycaemia,
hypertension, vertigo, deafness, Cushingoid features, pruritis, polyarthralgia,
streptomycin reaction, rifampicin flu, rash, and others.
3. Coma clearance time.
4. Fever clearance time.
5. Time to discharge.
6. Time to relapse.
7. Presence of focal neurological deficit (9 months post-randomization).
Assessed during 5-year follow-up study (9 months to 5 years post-randomization)
1. Death.
2. Disability status.
3. TB relapse.
Notes Date: April 2001 to March 2003 (randomization period).
Trialists: Oxford University Clinical Research Unit at the Hospital for Tropical Diseases,
Ho Chi Minh City, Vietnam, and Pham Ngoc Thach Hospital for Tuberculosis and
Lung Disease, Ho Chi Minh City, Vietnam, in collaboration with Centre for Tropical
Medicine, Nuffield, and Department of Clinical Medicine, John Radcliffe Hospital,
Oxford, UK
In this trial, 187/545 participants were acid-fast stain/culture positive for M. tuberculosis
in CSF.
Participants were reclassified to “definite” tuberculous meningitis if participant CSF was
culture positive forM. tuberculosis, or to “not TBM” if an alternative diagnosis was made.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-generated sequence of ran-
dom numbers was used to allocate treat-
ment in blocks of 30.”
Allocation concealment (selection bias) Low risk “Numbered individual treatment packs
containing the study drug were prepared
for the duration of treatment and were
distributed for sequential use once a pa-
tient fulfilled the entry criteria. Parenteral
placebo and dexamethasone were identical
in appearance, aswere oral placebo anddex-
amethasone.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “All participants, enrolling physicians, and
investigators remained blinded to the treat-
ment allocation until the last patient com-
pleted follow-up.”
In five-year follow-up study: no blinding.
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Blinding of outcome assessment (death) Low risk “All participants, enrolling physicians, and
investigators remained blinded to the treat-
ment allocation until the last patient com-
pleted follow-up.”
In five-year follow-up study: no blinding,
unlikely to introduce risk of bias for all-
cause mortality
Blinding of outcome assessment (disabling
neurological deficit at the end of follow-up)
Low risk “All participants, enrolling physicians, and
investigators remained blinded to the treat-
ment allocation until the last patient com-
pleted follow-up.”
In five-year follow-up study: no blinding,
risk of bias was unclear for neurological dis-
ability
Incomplete outcome data (attrition bias)
All outcomes
Low risk Lost to follow-up (initial study): 5/274 in
dexamethasone arm and 5/271 in placebo
arm
Lost to follow-up (5-year follow-up study):
18/274 in dexamethasone arm and 22/271
in placebo arm
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported as per
protocol.
Abbreviations: CT: computerized tomography;HIV: human immunodeficiency virus;MRC:Medical ResearchCouncil;M. tuberculosis:
Mycobacterium tuberculosis complex; CSF: cerebrospinal fluid; ATT: antituberculous treatment; TBM: tuberculous meningitis; TB:
tuberculosis.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Donald 2004 Perspective article with no original data.
Escobar 1975 Not a randomized study. The report says that a pair of participants matched for age and neurological status
was administered differential therapy in a double-blind fashion. However, it is unclear if this differential
administration was random
Freiman 1970 Case series.
Girgis 1983 Participants allocated to steroid or non-steroid group on alternate basis; unclear why there is a difference of 4
in the number of participants in the 2 groups (non-steroid 70 and steroid 66)
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(Continued)
Heemskerk 2016 RCT comparing standard ATT regimen with an intensified ATT regimen, all participants received dexam-
ethasone
Hockaday 1966 Case series.
Kalita 2001 Study with historical controls, not a randomized study.
Kapur 1969 Case series.
Karak 1998 Commentary on an included trial (Schoeman 1997).
Lepper 1963 Allocation was not truly randomized: the first half of the study was an alternate participant design, whereas in
the last half, participants were randomized by using random numbers
Marras 2005 Letter to the editor with no original data.
Quagliarello 2004 Editorial.
Seligman 2005 Letter to the editor with no original data.
Shah 2014 RCT comparing three different doses of prednisolone; no placebo arm
Vagenakis 2005 Letter to the editor with no original data.
Voljavec 1960 Comparison cohort with historical controls.
Wasz-Höckert 1963 Control trial using historical controls.
Weiss 1965 Retrospective case series of 102 cases.
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D A T A A N D A N A L Y S E S
Comparison 1. Any corticosteroid versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Follow-up at 2 to 24
months
9 1337 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.65, 0.87]
1.2 Follow-up at 2 years 1 545 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.67, 1.01]
1.3 Follow-up at 5 years 1 545 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.78, 1.12]
2 Disabling neurological deficit 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Follow-up 2 to 24 months 8 1314 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.71, 1.20]
2.2 Follow-up at 5 years 1 244 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.46, 1.58]
3 Death or disabling neurological
deficit
8 1314 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.72, 0.89]
4 Adverse events 4 2620 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.67, 1.17]
4.1 Hyperglycaemia/
glycosuria
3 627 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [0.40, 8.36]
4.2 Hepatitis 2 642 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.57, 1.09]
4.3 Gastrointestinal bleeding 4 724 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.61, 3.48]
4.4 Invasive bacterial infection 3 627 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.36, 1.93]
Comparison 2. Any corticosteroid versus control: stratified by severity of illness
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 8 1320 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.57, 0.80]
1.1 Stage I (mild) 6 305 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.29, 0.85]
1.2 Stage II (moderately
severe)
7 581 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.56, 0.93]
1.3 Stage III (severe) 8 434 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.54, 0.88]
Comparison 3. Any corticosteroid versus control: stratified by HIV status
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 534 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.66, 1.02]
1.1 HIV-positive 1 98 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.67, 1.20]
1.2 HIV-negative 1 436 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.58, 1.06]
2 Disabling neurological deficit 1 534 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.73, 1.79]
2.1 HIV-positive 1 98 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.08, 19.07]
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2.2 HIV-negative 1 436 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.73, 1.80]
3 Death or disabling residual
neurological deficit
1 545 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.76, 1.09]
3.1 HIV-positive 1 98 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.68, 1.20]
3.2 HIV-negative 1 447 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.74, 1.14]
Comparison 4. Sensitivity analysis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Worst case scenario analysis 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Worst case: death 6 911 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.66, 0.96]
1.2 Available case: death 6 882 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.59, 0.86]
A D D I T I O N A L T A B L E S
Table 1. Summary of characteristics of included trials
Trial ID Coun-
try
Year Setting Age TB
menin-
gi-
tis MRC
Gradea
HIV
status
re-
ported
TB
treat-
ment
regimen
b
Steroid Route Starting
dose
Dura-
tion
O’Toole
1969
India 1966 to
1967
Tertiary All II and III No HS (du-
ration
not spec-
ified)
Dexam-
ethasone
IM/IV Adults: 9
mg/day
Chil-
dren: un-
clear
4 weeks
Girgis
1991
Egypt 1982 to
1987
Research All All No 24HE1.
5S
Dexam-
ethasone
IM Adults:
12 mg/
day
Chil-
dren: 8
mg/day
6 weeks
Kumar-
velu
1994
India 1991 to
1992
Tertiary > 12
years
All No 12HRZ Dexam-
ethasone
IV 16 mg/
day
4 weeks
Chot-
mongkol
1996
Thai-
land
1990 to
1992
Tertiary > 15
years
All Yes,
HIV-
pos-
itive par-
ticipants
2HRZS+4HR
Pred-
nisolone
Oral 60 mg/
day
5 weeks
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Table 1. Summary of characteristics of included trials (Continued)
excluded
Schoe-
man
1997
South
Africa
Unclear Tertiary Chil-
dren
II and III No 6HRZE Pred-
nisolone
Oral 2 to
4 mg/kg/
day
4 weeks
Lardiza-
bal
1998
Phillip-
ines
1996 to
1997
Tertiary > 18
years
II and III No
2HRZE+10HR
Dexam-
ethasone
IV/oral 16 mg/
day
7 weeks
Thwaites
2004
Vietnam 2001 to
2003
Tertiary > 14
years
All Yes,
HIV
partici-
pants in-
cluded
3HRZE
(or S)
+6HRZ
Dexam-
ethasone
IV Grade II
& III: 0.
4 mg/kg/
day
Grade I:
0.3 mg/
kg/day
8 weeks
Prasad
2006
India 1996
onwards
Tertiary > 16
years
All No 9RHZ Dexam-
ethasone
IV 0.6 to 12
mg/day
3 weeks
then ta-
pered
Malho-
tra
2009
India 2006 to
2007
Tertiary > 14
years
All Yes,
HIV-
pos-
itive par-
ticipants
excluded
2HRZE
(or S)
+7HR
Dexam-
ethasone
IV 0.4 mg/
kg/day
8 weeks
Methyl-
pred-
nisolone
IV 20 mg/
kg/day
5 days
aTB meningitis MRC Grade: I = mild cases with no altered consciousness or focal neurological signs; II = moderately advanced cases
with reduced conscious level but not comatose or with moderate neurological deficits, or both (for example, single cranial nerve
palsies, paraparesis, and hemiparesis); III = severe cases including comatose participants, or participants with multiple cranial nerve
palsies, hemiplegia or paraplegia, or both.
bTB treatment regimen: H = isoniazid; R = rifampicin; Z = pyrazinamide; S = streptomycin; E = Ethambutol; the number = number
of months of treatment.
Abbreviations: TB: tuberculosis; IM: intramuscular; IV: intravenous
Table 2. Diagnostic criteria used in the included trials
Trial ID Number of participants with microbiologically-
confirmed tuberculous meningitisa (percentage)
Other diagnostic criteria
Steroid group Control group
O’Toole 1969 8/11 (72.7) 6/12 (50) Not described.
Girgis 1991 75/145 (51.7) 85/135 (63.0) Characteristic clinical features and CSF findings, plus
poor response to broad spectrum antibiotics
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Table 2. Diagnostic criteria used in the included trials (Continued)
Kumarvelu 1994 Not reported Not reported Characteristic clinical, CSF and CT findings. Pyo-
genic meningitis and malignancy excluded
Chotmongkol 1996 4/29 (13.8) 1/30 (3.3) Characteristic clinical and CSF findings, negative la-
tex agglutination tests on CSF for bacterial and cryp-
tococcal antigens, negative CSF cytology for malig-
nant cells, negative serology for syphilis and HIV
Schoeman 1997 56/141 (39.7) had culture-positive gastric aspirate
23/141 (16.3) had culture-positive CSF
Characteristic clinical and CSF findings, plus two or
more of: positiveMantoux test, chest X-ray suggestive
of TB, CT brain with acute hydrocephalus and basal
enhancement
Lardizabal 1998 Not reported Not reported “Probable TBM” if characteristic clinical and CSF
findings, negative latex agglutination test on CSF for
cryptococcal antigen plus one or more of meningeal/
basilar enhancement on contrast CT brain, positive
PPD, history of contactwithTBparticipant, evidence
of active pulmonary TB
“Confirmed TBM” if CSF microscopy positive for
AFBs on Ziehl-Nielsen staining, or culture positive
for MTB, or both
Thwaites 2004 98/274 (35.8) 89/271 (32.8) “Probable” TBM if one or more of chest X-ray sug-
gestive of TB, AFB in non-CSF specimen, clinical ev-
idence of other EPTB
“Possible” TBM if 4 of history of TB, lymphocytic
CSF, ill for more than 5 days, CSF:plasma glucose
ratio less than 0.5, altered consciousness, yellow CSF,
focal neurological signs
Prasad 2006 Not reported Not reported Characteristic clinical and CSF findings. Pyogenic
meningitis and malignancy excluded
Malhotra 2009 4/30 (13.3) 15/61 (24.6) “Probable” TBM if one or more of chest X-ray sug-
gestive of TB, AFB in non-CSF specimen, clinical ev-
idence of other EPTB
“Possible” TBM if 4 of history of TB, lymphocytic
CSF, ill for more than 5 days, CSF:plasma glucose
ratio less than 0.5, altered consciousness, yellow CSF,
focal neurological signs
aReferring to positive microbiological test on CSF, including microscopy for acid-fast bacilli, mycobacterial culture and PCR-based
methods.
Abbreviations: TBM: tuberculous meningitis; CSF: cerebrospinal fluid; CT: computer tomography; HIV: human immunodeficiency
virus; EPTB: extrapulmonary tuberculosis; AFB: MTB.
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Table 3. Corticosteroid dose regimens used in the included trials
Trial Steroid Dose regimen
Adults Children
O’Toole 1969 Dexamethasone IV 9 mg daily for 7 days
6 mg daily for 7days
3 mg daily for 7 days
1.5 mg daily for 7 days
Derived from a standard table based on
surface area.
Girgis 1991 Dexamethasone IM 12 mg daily for 21 days, then tapered
over 21 days
8mg daily if weight less than 25 kg, then
tapered over 21 days
Kumarvelu 1994 Dexamethasone 16 mg IV daily for 7 days
8 mg PO daily for 21 days
0.6 mg per kg daily for 7 days
0.3 mg per kg daily for 21 days
Chotmongkol 1996 Prednisolone 60 mg daily for 7 days
45 mg daily for 7 days
30 mg daily for 7 days
20 mg daily for 7 days
10 mg daily for 7 days
--
Schoeman 1997 Prednisolone n/a 2 mg/kg daily (first 16 participants)
4 mg/kg daily (remaining 54 partici-
pants)
Lardizabal 1998 Dexamethasone 16 mg daily for 21 days (IV for first 5
days, PO/NG thereafter)
12 mg daily for 5 days
8 mg daily for 5 days
4 mg daily for 5 days
--
Thwaites 2004 Dexamethasone Grade II and III disease:
IV therapy
0.4 mg per kg daily for 7 days
0.3 mg per kg daily for 7 days
0.2 mg per kg daily for 7 days
0.1 mg per kg daily for 7 days
Then oral therapy starting at 4 mg per
day and decreasing by 1 mg every 7 days
Grade I disease:
IV therapy
0.3 mg per kg daily for 7 days
0.2 mg per kg daily for 7 days
Then oral therapy
0.1 mg per kg daily for 7 days
3 mg per day decreasing by 1 mg every
7 days
--
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Table 3. Corticosteroid dose regimens used in the included trials (Continued)
Prasad 2006 Dexamethasone 0.15 mg per kg (up to a maximum of
4mg) every 6 hours for 21 days then ta-
pered gradually
--
Malhotra 2009 Dexamethasone IV 0.4 mg per kg daily for 7 days
0.3 mg per kg daily for 7 days
0.2 mg per kg daily for 7 days
0.1 mg per kg daily for 7 days
--
Methylprednisolone IV 1 g per day for 5 days (if weight over 50
kg)
20 mg/kg
(if weight under 50 kg)
Abbreviations: IV: intravenous; IM: intramuscular; n/a: not applicable.
Table 4. Disabling/non-disabling terms used in this review: mapped onto terms in primary trials
Trial ”Disabling“ as defined in this Cochrane Review ”Non-disabling“ as defined in this Cochrane Re-
view
Girgis 1991 Permanent residual neurological sequelae, including
hydrocephalus, hemiparesis and fundus abnormalities
Not described.
Kumarvelu 1994 Major sequelae: persistent vegetative state, blind,
symptomatic hydrocephalus, moderate-severe intel-
lectual impairment, severe functional disability (to-
tally dependent)
Minor sequelae: mild intellectual impairment, mild
to moderate functional disability (activities of daily
living with no/minimal assistance) or no sequelae
Chotmongkol 1996 Persisting neurological abnormalities, including de-
creased vision, spastic paraparesis and hemiparesis
Not described.
Schoeman 1997 Severe disability: “One or more of the following
present: IQ (DQ) less than 75, quadriparesis, and
blindness or deafness”
Healthy: “IQ (DQ) greater than 90; no motor or sen-
sory deficit”
Mild disability: “One or more of the following
present: IQ (DQ) 75 to 90, hemiparesis, and de-
creased vision or hearing”
Lardizabal 1998 Functional Independence Measure:
Score 18 to 36: severely disabled, requiring maximal
to total assistance. The subject can carry out less than
25% of the activities for self-care, sphincter control,
mobility, locomotion, communication and cognition
Score 37 to 54:moderate to severe disability, requiring
moderate tomaximal assistance. The subject can carry
out more than 25 to 50 % of the activities for self-
care, sphincter control, mobility, locomotion, com-
munication and cognition
Functional Independence Measure:
Score 55 to90:minimal tomoderate disability, requir-
ing onlyminimal assistance. The subject can carry out
more than 50% of the activities of self-care, sphincter
control, mobility, locomotion, communication and
cognition
Score 91-126: minimal disability to functionally in-
dependent. The subject requires no assistance in self-
care, sphincter control, mobility, Iocomotion, com-
munication, cognition
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Table 4. Disabling/non-disabling terms used in this review: mapped onto terms in primary trials (Continued)
Thwaites 2004 Severe disability: “Severe disability: assessed on
Rankin scale (assessor reported outcome) AND “sim-
ple questions” (patient reported outcome)
Rankin scale - “3 indicated symptoms that restricted
lifestyle and prevented independent living; 4 indi-
cated symptoms that prevented independent living,
although constant care and attention were not re-
quired; and 5 indicated total dependence on others,
requiring help day and night”
Scores of 3, 4 or 5 indicated severe disability.
“simple questions” - 2 simple questions on recovery
(question 1: do you feel that you have made a com-
plete recovery?) and dependency (question 2: do you
require help from another person for everyday activi-
ties?) “yes” to either indicates severe disability
Good outcome: Rankin score 0 indicating no symp-
toms. ‘No’ to all simple questions
Intermediate outcome: Rankin score 1 or 2. “1 indi-
cated minor symptoms not interfering with lifestyle;
2 indicated symptoms thatmight restrict lifestyle, but
patients could look after themselves”
‘No’ to simple questions, but ‘yes’ to follow-up ques-
tion asking about “any other problems”
Prasad 2006 ”Bad outcome: If the patient has neither recovered
nor is independent in activities of daily living“
”Functionally independent: If the patient is indepen-
dent in activities of daily living. He may or may not
have got minimal residual neurological deficit“
Malhotra 2009 Severe disability:
Rankin score of 3, 4 or 5.
“A subject with moderate disability (requiring some
help, but able to walk without assistance) is scored 3,
one with moderately severe disability (unable to walk
without assistance and unable to attend to own bodily
needs without assistance) is scored 4, while a patient
who is bedridden, incontinent and requiring constant
nursing care and attention is scored 5”
Good outcome:
Rankin score 0. “A score of 0 indicates that there are
no symptoms at all”
Intermediate outcome:
Rankin score of 1 to 2. “A score of 1 indicates no sig-
nificant disability despite the presence of symptoms
(with the subject able to carry out all their usual duties
and activities) and a score of 2 indicates slight disabil-
ity (with the subject unable to carry out all their pre-
vious activities, but able to look after their own affairs
without assistance)”
Abbreviations: IQ: intelligence quotient; DQ: development quotient
Table 5. Adverse events
Trial Severity Event Corticosteroid
n out of total in group
Control
n out of total in group
O’Toole 1969a - Gastrointestinal bleeding 5 5
Glycosuria 1 0
Infections 2 5
Hypothermia 5 1
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Table 5. Adverse events (Continued)
Schoeman 1997b - “Serious side effects” 0 0
Thwaites 2004c Severe Hepatitis (severe) 0 8
Gastrointestinal bleeding (se-
vere)
2 3
Bacterial sepsis (severe) 3 4
Hyperglycaemia (severe) 0 0
Other Subclinical hepatitis 0 0
Septic shock 3 0
Brain herniation syndrome 1 4
Decrease in visual acuity 6 8
Hyponatraemia 1 6
Hypertension 0 0
Vertigo 0 0
Deafness 3 3
Cushing’s features 0 0
Pruritis 0 0
Polyarthralgia 0 0
Streptomycin reaction 0 0
Rifampicin ’flu’ 0 0
Rash 1 0
Malhotra 2009d - Hepatitis 12 8
Anti-epileptic toxicity 4 3
Gastrointestinal bleeding 6 1
Paradoxical tuberculoma 3 5
Abbreviations; n: number of participants with event.
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aO’Toole 1969: n/11 participants in corticosteroid arm; n/12 participants in control arm.
bSchoeman 1997: n/67 participants in corticosteroid arm; n/67 participants in control arm.
cThwaites 2004: n/274 participants in corticosteroid arm; n/271 participants in control arm.
dMalhotra 2009: n/61 participants in corticosteroid arm; n/30 participants in control arm.
WH A T ’ S N E W
Date Event Description
13 April 2016 New citation required but conclusions have not changed We included nine trials in total, and the review’s conclu-
sions remain unchanged
13 April 2016 New search has been performed Hannah Ryan joined the review author team. We in-
cluded two new trials (one published and one unpub-
lished), added published follow-up data from Thwaites
2004, and constructed ’Risk of bias’ tables and a ’Sum-
mary of findings’ table. We presented outcomes for dis-
abling neurological deficit separately following feedback,
reviewed all included studies, and re-extracted data. We
rewrote the Results and Discussion sections, and revised
the plain language summary.
H I S T O R Y
Date Event Description
14 November 2007 New citation required but conclusions have not
changed
2008, Issue 1: we added one new trial, Thwaites 2004.
We updated the review text and title.MB Singh joined
the author team, and J Volmink and GR Menon
stepped down from the author team
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sections of the review. MB Singh also screened the search results, assessed methodological quality, extracted data, and entered data
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assessment, constructed a ’Summary of findings’ table with GRADE assessment, and revised the Background, Results, and Discussion
sections.
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